# A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

> **NCT07532603** · PHASE2,PHASE3 · RECRUITING · sponsor: **Priovant Therapeutics, Inc.** · enrollment: 342 (estimated)

## Conditions studied

- Lichen Planopilaris

## Interventions

- **DRUG:** Oral Brepocitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07532603
- **Lead sponsor:** Priovant Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532603, "A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07532603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*